Literature DB >> 2835944

Suppression of humoral immune response against herpes simplex virus induced by defective strains, ts- and TK- mutants.

B Metzger1, J Podlech, S Müller, D Falke.   

Abstract

Suppression of humoral antibody formation against HSV is not only induced by replicating Herpes simplex virus type 2 (HSV-2) but also by the defective strain ANG and the deletion mutant 1301 of Herpes simplex virus type 1 (HSV-1). Moreover, ts-mutants A, H, K, S, 1201 and 1208 of HSV-1 as well as some ts-mutants of HSV-2 and "defective-interfering" particles of HSV-1 after high multiplicity of infection-passages induced suppression. Treatment of infected mice with ACG reduced antibody-formation but did not result in suppression. UV-irradiation of the antibody producing strain Len of HSV-1 strongly reduces antibody formation and induces suppression. Experiments using a series of intertypic recombinants showed the suppressing activity to be spread over the whole genome of HSV-2. It is concluded that suppression is induced by more than one region of the genome of HSV-2 and by incomplete replication of HSV-1 and 2.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2835944     DOI: 10.1007/BF01311065

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  11 in total

1.  Structure and origin of defective genomes contained in serially passaged herpes simplex virus type 1 (Justin).

Authors:  H Locker; N Frenkel
Journal:  J Virol       Date:  1979-03       Impact factor: 5.103

2.  Processing of viral antigens and presentation to class II-restricted T cells.

Authors:  K H Mills
Journal:  Immunol Today       Date:  1986-09

3.  Amplification of a short nucleotide sequence in the repeat units of defective herpes simplex virus type 1 Angelotti DNA.

Authors:  H C Kaerner; A Ott-Hartmann; R Schatten; C H Schröder; C P Gray
Journal:  J Virol       Date:  1981-07       Impact factor: 5.103

4.  Virus-specific IgM and IgG antibody production by B cells during herpes simplex virus type 2-induced immunosuppression as analysed by an immunospot assay.

Authors:  S Nick; B Metzger; S Muller; D Falke
Journal:  J Gen Virol       Date:  1987-07       Impact factor: 3.891

5.  Fusion from without induced by herpes simplex virus type 1.

Authors:  D Falke; A Knoblich; S Müller
Journal:  Intervirology       Date:  1985       Impact factor: 1.763

6.  Suppression and enhancement of humoral antibody formation by herpes simplex virus types 1 and 2.

Authors:  S Nick; P Kampe; A Knoblich; B Metzger; D Falke
Journal:  J Gen Virol       Date:  1986-06       Impact factor: 3.891

7.  Replication of HSV-1 in murine peritoneal macrophages: comparison of various virus strains with different properties.

Authors:  J Görtz; B Brake; V Härle-Grupp; D Falke
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

8.  Thymidine kinase deletion mutants of herpes simplex virus type 1.

Authors:  P G Sanders; N M Wilkie; A J Davison
Journal:  J Gen Virol       Date:  1982-12       Impact factor: 3.891

9.  Differences in humoral immunogenicity between herpes simplex virus types 1 and 2.

Authors:  P Kampe; A Knoblich; M Dietrich; D Falke
Journal:  J Gen Virol       Date:  1985-10       Impact factor: 3.891

10.  Ultrastructural characterization of herpes simplex virus type 1 (strain 17) temperature-sensitive mutants.

Authors:  D Dargan; J H Subak-Sharpe
Journal:  J Gen Virol       Date:  1983-06       Impact factor: 3.891

View more
  4 in total

1.  The region 0.7615-0.796 m.u. of the HSV-1 genome determines suppression of humoral antibody formation against herpes simplex virus.

Authors:  K Wollert; T el Ansari; A Rösen-Wolff; D Falke
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

2.  Suppression of humoral antibody formation against sheep red blood cells by infections with HSV-2 and the influence of mouse cytomegalovirus. Brief report.

Authors:  S Nick; B Metzger; S Jonsić; D Falke
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

3.  Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice.

Authors:  Natalie V Akhrameyeva; Pengwei Zhang; Nao Sugiyama; Samuel M Behar; Feng Yao
Journal:  J Virol       Date:  2011-03-09       Impact factor: 5.103

4.  Intravaginal Zinc Oxide Tetrapod Nanoparticles as Novel Immunoprotective Agents against Genital Herpes.

Authors:  Thessicar E Antoine; Satvik R Hadigal; Abraam M Yakoub; Yogendra Kumar Mishra; Palash Bhattacharya; Christine Haddad; Tibor Valyi-Nagy; Rainer Adelung; Bellur S Prabhakar; Deepak Shukla
Journal:  J Immunol       Date:  2016-04-27       Impact factor: 5.422

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.